New research reveals that people who discontinue new GLP-1 drugs like Mounjaro or Wegovy may regain reduced body mass far faster than those who halt traditional diet and exercise regimens.
Research printed in a leading health publication points out that while overweight individuals often shed a large proportion of their total mass while undergoing treatment, the weight comes back at an average rate of 0.8 kg per month upon discontinuation.
"People buying these medications must be cognizant of the potential of quick rebound weight gain when the therapy is stopped," warns lead investigator Dr. Susan Jebb.
That rate of recovery implies a reversion to original mass in about one and a half years.
Analyzing Treatments
The analysis, which reviewed dozens of studies involving over 9,000 of patients, contrasted the outcomes of GLP-1 agonists with older methods.
The team point out that individuals who lose weight through diet and exercise generally see a more gradual weight regain—around 100 grams monthly—after stopping.
The Reason for the Quick Rebound
Experts believe the mechanism of the injections explains the accelerated rebound.
GLP-1 drugs mimic a body's own chemical called GLP-1, which moderates feelings of fullness.
"Sustained high doses of GLP-1 levels far above than normal may cause the system to produce less of its endogenous GLP-1, and may also diminish responsiveness to its actions," explained Dr. Adam Collins, a nutrition specialist.
"Stopping of this medication leads to appetite is unsuppressed, making overeating much more probable."
An Ongoing Disease?
Medical guidelines recommend the injections for individuals with obesity-related medical conditions, accompanied by recommended diet and exercise modifications.
Many experts contend that, given the high risk of relapse, the treatment is often life-long.
This perspective is reinforced by pharmaceutical companies, who state that the results "emphasize the long-term nature of excess weight," akin to managing conditions like hypertension.
Patient Experiences
Users who have discontinued the jabs describe a powerful return of hunger.
"I experienced something activating and I was suddenly extremely hungry," described an individual.
This challenge is exacerbated if patients have not developed lasting lifestyle or habit modifications during treatment.
Widespread Use
Recent estimates indicate that millions of adults in the UK have used these injections in the past year, with interest remaining high.
- Adoption is higher among females than males.
- The middle-aged age group shows the greatest usage rates.
- A large proportion access the drugs through private prescriptions rather than public health services.
In conclusion, experts stress that while these medications are potent tools for weight loss, they are not a magic fix and lasting health benefits relies on ongoing lifestyle changes.
